Medical Therapy in Patients with Moderate to Severe, Steroid-resistant, Thyroid Eye Disease.

David Toro-Tobon,Kharisa Rachmasari,Elizabeth Bradley,Lilly Wagner,Andrea A Tooley,Janalee K Stokken,Marius N Stan

Thyroid : official journal of the American Thyroid Association（2023）

引用 0|浏览0

暂无评分

摘要

Teprotumumab and tocilizumab improved inflammation in patients with moderate to severe TED who had failed previous steroid therapy. Additionally, the teprotumumab cases demonstrated similar improvement in proptosis and diplopia to the teprotumumab controls. Further evaluation, particularly regarding long term response and side-effect profile, of these medications in steroid-resistant TED is needed.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要